Windtree Therapeutics (NASDAQ: WINT) and Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.
This is a summary of recent recommendations and price targets for Windtree Therapeutics and Tetralogic Pharmaceuticals Corp, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
Windtree Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 4,110.53%. Given Windtree Therapeutics’ higher possible upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Tetralogic Pharmaceuticals Corp.
This table compares Windtree Therapeutics and Tetralogic Pharmaceuticals Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
Institutional and Insider Ownership
36.8% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. 1.3% of Windtree Therapeutics shares are held by insiders. Comparatively, 24.0% of Tetralogic Pharmaceuticals Corp shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Windtree Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500.
Valuation & Earnings
This table compares Windtree Therapeutics and Tetralogic Pharmaceuticals Corp’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Windtree Therapeutics||$3.23 million||0.82||-$28.34 million||($5.25)||-0.04|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-$21.14 million||($1.76)||-0.02|
Tetralogic Pharmaceuticals Corp has higher revenue, but lower earnings than Windtree Therapeutics. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals Corp, indicating that it is currently the more affordable of the two stocks.
Tetralogic Pharmaceuticals Corp beats Windtree Therapeutics on 6 of the 10 factors compared between the two stocks.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.